Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Data, At Last | Main | Fan Mail »

June 21, 2005

Morphine in the Brain: Go For It, or Not?

Email This Entry

Posted by Derek

So, I do a post where I wonder if the reductionist target-driven approach to drug discovery is running out of gas, then I do one on the possibility of some interesting new drug targets in the brain. Am I deliberately talking out of both sides of my mouth, or do I just not remember what I've written the day before?

Actually, I can hold both of those views simultaneously. Order now and I'll send you my exciting at-home kit which will allow you to do the same! Here's how it's done: the morphine-synthesizing enzymes in brain cells that I spoke about yesterday are, indeed, possible drug targets. But I'm defining "target" pretty loosely here, as "theoretical possibility for therapeutic intervention." The step beyond that is "validated target", and we're a long way from that.

The problem is, no one has the faintest idea what brain cells are up to when they make morphine. I should start out by saying that we don't know which brain cells, of the insane number of different types, actually make it in vivo, what parts of the brain they're located in, or what factors cause them to increase or decrease its production. And once it's made, we don't know what it does or why. Presumably it's binding to the known opioid receptors, whose biology was complicated enough already, thanks. (See this recent paper, pointed out in a comment to the last post.) But there are already families of endogenous peptides that do that, so you have to wonder why morphine is in there, too. Under physiological conditions, perhaps there are other signaling roles for it (intracellular ones, maybe?) of which we are entirely ignorant.

But it's fair to assume that it's in there for a reason, and it's also fair to assume that disrupting its production would have an effect, even if we don't know that that might be. That makes endogenous morphine production a potential target, and an interesting one. But if we wait until these questions are well worked out, we could be in for a long wait. That's been the problem with many molecular-level targets, and Monday's post spoke about some of the difficulties with them.

How do you get more information? One way to approach the problem would be to disrupt one of the key enzymes used in endogenous morphine synthesis, once we know what they are, and see what happens. You could do that with RNA interference in cell cultures, but it can be hard to see what the effects are unless you touch on something vital. That's especially true with CNS targets, because cells in a dish are an extremely poor surrogate for the complex properties of the intact brain. A better route would be to go into whole animals: you could knock out the enzyme in mice and see how they develop, but the big question with knockout animals is how they compensate during development for that induced loss of function. Sometimes the changes you bring on end up being too subtle to catch, and you get what looks just like a normal mouse.

You'd probably be better off with a small-molecule enzyme inhibitor which could be dosed in a normal adult animal. If it's selective and nontoxic enough, you'd have a chance to see what the loss of endogenous morphine does under real-world conditions - assuming that it's something that can be noticed at all in an animal model, and assuming that you're sharp-eyed enough to catch it. Does it affect motor control, memory, emotional state, sensory input, or what? If you give it to a rat and he goes off and flops down, is that because he's dizzy, because his legs don't feel right, because he feels sick to his stomach, because he's suddenly sleepy, or because he's overcome with waves of rodent ennui? You can untangle some of those, but it isn't easy. You'd know, though, that it certainly does something, even if you're not quite sure what it is.

So, your choices are: go with the molecular approach, but be prepared to wait years for answers. (Be prepared to wait decades if the answer ends up requiring a molecular-level understanding of something like long-term memory or emotional state.) Or, go with the whole-animal approach once you've got some idea of the target, but be prepared to see no changes, or changes that you're unable to interpret or extrapolate to humans.

What I'd do, were I in charge of such an effort, is give the molecular approach some time at the beginning to see if they could narrow things down a bit. Is morphine made only in the brain, or also in the peripheral nervous system or also in other tissues entirely? What regions of the brain look most important? What enzyme should we be targeting to best affect the whole system? These could take a while, but not as long as working out the whole story would. Once we had some idea about the enzyme, I'd turn around and screen against it, looking for some chemical matter to try animal studies with. Getting something suitable might be a matter of months, or it might be a matter of years. How much time and money were you thinking about spending? This would be a major effort, clearly, and one unlikely to take place inside one research organization, no matter how dedicated and well-funded.

But here's the problem: this target, compared to some of the things that came spilling out during the genomics craze, is actually pretty well-grounded. Think about it - we have receptors that we know will bind morphine, and a lot is known about their biology (even if we don't understand what morphine is doing in there with them in vivo.) We're pretty sure that this will be a CNS target, rather than, say, cancer or diabetes (although I'd never say never until I saw more data.) We even know what kind of enzymes to search for in the morphine biosynthesis pathway, based on what we know from plants.

No, although I've just spent all this time talking about how hard it would be, this project would have a real head start compared to many of the things out there. And if you find that a bit unnerving, then you can see why the strict molecular from-the-bottom-up approach is running into problems.

Comments (3) + TrackBacks (0) | Category: Drug Development | The Central Nervous System


COMMENTS

1. The Novice Chemist on June 22, 2005 12:40 AM writes...


You know, there's an NIH proposal in all of this somewhere... I think it's remarkable that the brain actually does synthetic chemistry at that level (perhaps I'm just very naive about the brain, which I am.)

Permalink to Comment

2. Peter Ellis on June 22, 2005 3:26 AM writes...

Surely we already have a slew of different opioid antagonists such as naloxone? Or do they block the peptide ligands as well?

Permalink to Comment

3. Derek Lowe on June 22, 2005 9:31 AM writes...

Yep, the opioid-based antagonists (like naloxone, methylnaltrexone, etc.) will block the peptides from binding, too. They're clogging up the various opioid receptor subtypes, so they'll keep everything else from binding.

That's what's so odd about endogenous morphine. Why do we have such different classes of things that seemingly bind to the same receptors? And that's why I think that the best shot at unraveling this will come from disrupting the endogenous morphine production.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Scripps Update
What If Drug Patents Were Written Like Software Patents?
Stem Cells: The Center of "Right to Try"
Speaking of Polyphenols. . .
Dark Biology And Small Molecules
How Polyphenols Work, Perhaps?
More On Automated Medicinal Chemistry
Scripps Merging With USC?